DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Richard Gonzalez - 2 AbbVie - 1 Robert Michael - 1 Michael - 1 Gonzalez - 1 Rob - 1 Evan Seigerman - 1 Leroy Leo - 1
Top related locs:
Humira U.S Amgen Bengaluru New York
Top related orgs:
Abbott Laboratories - 1 AbbVie - 1 CNBC PRO - 1 Global - 1 BMO Capital - 1 Thomson - 1

Search resuls for: "Richard Gonzalez"


3 mentions found


☆ AbbVie taps longtime executive Robert Michael as new CEO, succeeding Richard Gonzalez
  + stars: | 2024-02-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Test tubes are seen in front of a displayed AbbVie logo in this illustration taken on May 21, 2021. AbbVie on Tuesday said longtime executive Robert Michael will become the company's new CEO, replacing Richard Gonzalez. Michael, who is AbbVie's president and chief operating officer, will become the company's second-ever CEO on July 1. Gonzalez, who has led the company since it spun out from Abbott Laboratories in 2013, will retire and become AbbVie's executive chairman. Now is the opportune time to hand the CEO role over to Rob," Gonzalez said in a release.
Persons: AbbVie, Robert Michael, Richard Gonzalez, Michael, Gonzalez, Rob Organizations: Abbott Laboratories, AbbVie, CNBC PRO Locations: Humira
☆ AbbVie raises profit forecast as Humira stays strong, new drugs impress
  + stars: | 2023-07-27 | by ( Leroy Leo Patrick Wingrove | Leroy Leo | Patrick Wingrove | ) www.reuters.com   time to read: +2 min
July 27 (Reuters) - AbbVie (ABBV.N) on Thursday raised its annual profit forecast after beating analysts' estimates for second-quarter earnings on a lower-than-expected fall in sales of blockbuster arthritis drug Humira and strong sales of newer treatments. Global Humira sales tumbled 25.2% to $4.01 billion while analysts had expected $3.94 billion, according to Refinitiv data. Still, Humira sales are expected to drop 37% in 2023, and the company has been leaning on newer immunology drugs Skyrizi and Rinvoq to drive growth. Excluding one-off items, AbbVie reported a profit of $2.91 per share, beating the average analyst estimate of $2.81. The company raised its 2023 adjusted profit forecast to $10.90 to $11.10 per share from $10.57 to $10.97 earlier.
Persons: Evan Seigerman, Richard Gonzalez, Leroy Leo, Patrick Wingrove, Sriraj Kalluvila, Jonathan Oatis Organizations: Global, BMO Capital, Reuters, Thomson Locations: U.S, Amgen, Bengaluru, New York
☆ AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira
  + stars: | 2023-02-06 | by ( Jared S. Hopkins | ) www.wsj.com   time to read: 1 min
Drugmaker AbbVie Inc. is looking for its next hit. Now that its blockbuster immune-disease therapy Humira is facing lower priced competition, AbbVie is turning to a pair of next-generation successors to replenish the billions of dollars in sales that will be lost, Chief Executive Richard Gonzalez said. It is also betting on four drug approvals by the end of next year.
0 next >>
Total: 3